Related Experiment Video
Updated: Jan 20, 2026

A Simple Composite Phenotype Scoring System for Evaluating Mouse Models of Cerebellar Ataxia
Published on: May 21, 2010
Molecular Mechanisms and Therapeutics for Spinocerebellar Ataxia Type 2
Polina A Egorova1, Ilya B Bezprozvanny2,3
1Laboratory of Molecular Neurodegeneration, Peter the Great St.Petersburg Polytechnic University, St. Petersburg, 195251, Russia.
Abstract:
The effective therapeutic treatment and the disease-modifying therapy for spinocerebellar ataxia type 2 (SCA2) (a progressive hereditary disease caused by an expansion of polyglutamine in the ataxin-2 protein) is not available yet. At present, only symptomatic treatment and methods of palliative care are prescribed to the patients. Many attempts were made to study the physiological, molecular, and biochemical changes in SCA2 patients and in a variety of the model systems to find new therapeutic targets for SCA2 treatment. A better understanding of the uncovered molecular mechanisms of the disease allowed the scientific community to develop strategies of potential therapy and helped to create some promising therapeutic approaches for SCA2 treatment. Recent progress in this field will be discussed in this review article.
Insights
Effective treatments for spinocerebellar ataxia type 2 (SCA2) are unavailable. This review discusses recent progress in understanding SCA2 molecular mechanisms to develop potential therapies and therapeutic targets.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Spinocerebellar ataxia type 2 (SCA2) is a progressive hereditary neurodegenerative disease.
- It is caused by polyglutamine expansion in the ataxin-2 protein.
- Currently, only symptomatic treatments and palliative care are available for SCA2 patients.
Purpose of the Study:
- To review recent progress in understanding the molecular mechanisms of SCA2.
- To discuss potential therapeutic targets and strategies for SCA2 treatment.
- To highlight promising therapeutic approaches for SCA2.
Main Methods:
- Review of existing literature on SCA2.
- Analysis of physiological, molecular, and biochemical changes in SCA2 patients and model systems.
- Discussion of emerging therapeutic strategies based on molecular insights.
Main Results:
- Understanding SCA2's molecular mechanisms has advanced significantly.
- Several promising therapeutic strategies and targets have been identified.
- Progress has been made in developing potential disease-modifying therapies.
Conclusions:
- Despite current limitations in effective treatment, research is yielding promising therapeutic avenues for SCA2.
- Further investigation into molecular mechanisms is crucial for developing disease-modifying therapies.
- The review highlights recent advancements and future directions in SCA2 therapeutic development.
Related Concept Videos
SN2 Reaction: Mechanism
The presence of the more electronegative halogen in the substrate creates a polarized carbon-halide bond. The halide pulls the electron cloud generating an electrophilic center at the carbon atom. Thus, the carbon atom carries a partial positive charge while the halide has a...
Diabetes Mellitus: Type 2 and Gestational
Reaction Mechanisms
For instance, the decomposition of ozone appears to follow a mechanism with two steps:
Molecular Orbital Theory II
Molecular Models
Molecular Orbital Theory I

